research SIÇANLARDA SODYUM VALPROAT KAYNAKLI MİDE HASARI ÜZERİNE RUTİN’İN OKSİDATİF STRES, İNFLAMASYON VE APOPTOZ ÜZERİNDEKİ KORUYUCU ETKİLERİNİN ARAŞTIRILMASI
Rutin may protect against stomach damage caused by sodium valproate.
Search
for
Sort by
Research
300-330 / 1000+ results 
research Case Report: Diffuse Hypertrichosis in the Course of Hepatitis C Treatment by IFN-α and Ribavirin
A man developed excessive hair growth after treatment with interferon-alpha and ribavirin for hepatitis C.
research ¿Novedad o prudencia? El delicado equilibrio en la actualización farmacológica
New drugs face challenges due to limited evidence, and safety updates are advised for some existing medications.
research Preliminary pharmacokinetics and metabolism of novel non-steroidal antiandrogens in the rat: Relation of their systemic activity to the formation of a common metabolite
Two non-steroidal antiandrogens, RU 58841 and RU 56187, form a common metabolite at different rates, which may influence their effects; RU 56187 could be used for prostate cancer treatment and RU 58841 for acne treatment.
research 842Combination therapy with rofecoxib and finasteride in the treatment of men with lower urinary tract symptoms (LUTS)
research Baricitinib-Induced Remission of Alopecia Universalis in a Child with NFKB2-Associated Immune Dysregulation
research Citalopram and finasteride with the lot number FI0510058-A have been voluntarily recalled by Greenstone, after a labelling error
research Alopecia universalis as a side effect of pegylated interferon α-ribavirin combination therapy for hepatitis C: a rare case report
A man lost all his hair as a rare side effect after hepatitis C treatment.
research Comparative efficacy and safety of JAK inhibitors in the treatment of moderate-to-severe alopecia areata: a systematic review and network meta-analysis
Brepocitinib 30mg is most effective for moderate-to-severe alopecia areata, but ritlecitinib 50mg may offer a better balance of safety and effectiveness.
research Acute and 30-day oral toxicity studies of a novel coccidiostat – ethanamizuril
Ethanamizuril is safe for rats at 20 mg/kg feed, but higher doses cause hair loss, organ changes, and liver, kidney, and lung damage.
research TMPRSS2, required for SARS-CoV-2 entry, is downregulated in lung cells by enzalutamide, a prostate cancer therapeutic
A prostate cancer drug can lower the levels of a protein that the coronavirus uses to enter lung cells.
research NUDT15 polymorphism explains serious toxicity to azathioprine in Indian patients with chronic immune thrombocytopenia and autoimmune hemolytic anemia: a case series
The NUDT15 gene variant causes severe side effects from azathioprine in some Indian patients.
research Drug pipeline 2Q22 — a downturn in approvals
Drug approvals slowed in 2Q22, but notable drugs like Amvuttra, Camzyos, and Olumiant were approved.
research Levetiracetam in the Treatment of Idiopathic Generalized Epilepsies
Levetiracetam is widely used and generally well-tolerated for treating idiopathic generalized epilepsies, with tiredness as the main side effect.
research Alfuzosin/finasteride
research Alfuzosin/finasteride
research Novel synthesis of nicotinamide derivatives of cytotoxic properties
Newly made nicotinamide compounds could potentially treat cancer.
research Rosacea-Like Dermatitis Caused by Icotinib Hydrochloride: A Case Report
A man developed skin issues from cancer medication, which improved with specific treatments.
research Janus Kinase Inhibitors for the Treatment of Severe Alopecia Areata: An Open-Label Comparative Study
Both ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata, but relapses are common.
research Timing of Initial Hair Regrowth and Clinical Trial-Defined Response Following Ritlecitinib Treatment in Patients With Alopecia Areata
Most patients with alopecia areata see significant hair regrowth within 93 days of starting ritlecitinib treatment.
research Synthesis and biological activity of raltitrexed-carrier conjugates.
Raltitrexed conjugates are less potent than the free drug but more effective at high concentrations.
research Teriflunomide in multiple sclerosis: an update
Teriflunomide effectively reduces relapses and disability in MS and has a manageable safety profile.
research LB1056 Phase 1b: Translational evaluation of VYN201, a pan-BD BET inhibitor, for the treatment of non-segmental vitiligo
VYN201 shows promise as a safe and effective treatment for non-segmental vitiligo.
research Dermatologic adverse events associated with afatinib: an oral ErbB family blocker
Afatinib often causes skin problems that need proactive management.
research Narrow-Band Ultraviolet B Phototherapy in Vitiligo
NB-UVB phototherapy is an effective and safe treatment for vitiligo, especially on hands and feet, and can be improved with tacrolimus.
research Drug repurposing of cyclin-dependent kinase inhibitors for neutrophilic acute respiratory distress syndrome and psoriasis
CDK inhibitors may help treat ARDS and psoriasis but need more testing for safety and effectiveness.
research Delayed granulomatous eruption of the nose associated with ruxolitinib
Ruxolitinib can cause a delayed skin reaction on the nose.
research MANAGEMENT OF NOTOEDRES CATI AND FELICOLA SUBROSTRATUS INFESTATION IN A MALE CAT
The cat's mite and lice infestations were successfully treated with medication and supportive care.
research NATURAL ANTIVIRALS FOR THE MANAGEMENT OF SARS-COVID-19: A REVIEW
Natural plant compounds may offer safer COVID-19 treatments with fewer side effects.
research New Drugs: Eculizumab
Eculizumab helps reduce blood transfusions and stabilize hemoglobin but increases infection risk and is expensive.